Clinical trials: cGVHD
Chronic Graft Versus Host Disease cGVHD
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD).
- Trial name
- NCT03422627
- Testing
- Efavaleukin Alfa
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 32 people
- Sponsor
- Amgen